Bacteriological and clinical studies on cefepime

Yoshihiro Sawae, Kaoru Okada, Toshiyuki Ishimaru, Koji Takaki, Nobuyuki Shimono, Hiroyasu Misumi, Yoshiyuki Niho

Research output: Contribution to journalArticlepeer-review


Bacteriological and clinical studies with cefepime (CFPM), a new parenteral cephalosporin antibiotic were performed, yielding the following results. 1. Antimicrobial activity The MICs of CFPM against various clinical isolates were determined with an inoculum size of 106 cells/ml. The MIC80 was 3.13 μ/ml for Staphylococcus aureus, 25 for Enterococcus faecalis, 0.05 for Escherichia coli, 0.20 for Klebsiella pneumoniae, 0.39 for Enterobacter spp. and Serratia marcescens, 0. 10 for Proteus spp., 0.78 for Citrobacter freundii, 6.25 for Acinetobacter calcoaceticus and 12.5 for Pseudomonas aeruginosa. Its activity against Gram-positive cocci was less than cefuzonam and cefmenoxime, but against Gram-negative rods, it was more active than ceftazidime, cefotaxime, cefmenoxime and cefuzonam. 2. Clinical efficacy One patient with pneumonia, 2 with purulent meningitis, 1 with sepsis, 1 with perianal abscess and 1 with ankylosing spondylitis were treated with CFPM at a daily dose of 2.0~4.0g for 3-17 days. Clinical response was excellent in 1, good in 1, fair in 1, poor in 2 and unknown in 1 patient. S. aureus, E. faecalis, Streptococcus milleri, Streptococcus mitis were eradicated by CFPM. No adverse reactions and no abnormal changes of laboratory investigations were observed.

Original languageEnglish
Pages (from-to)169-174
Number of pages6
Publication statusPublished - 1991

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of 'Bacteriological and clinical studies on cefepime'. Together they form a unique fingerprint.

Cite this